The AJA Foundation has been funding the Prostate Cancer Foundation (PCF) since 2007. We are gratified that our investment in research by PCF investigators has contributed to two new FDA approved treatments in one week. On May 20, 2020 the US Food and Drug Administration approved Lynparza as a viable treatment option for men effected by gene-mutated metastatic castration-resistant prostate cancer. On May 15, 2020 a new medication, Rubraca was approved to treat some patients with prostate cancer. These approvals are an important testament to the value of early foundational work which can bear multiple fruits in the form of new treatments, even many years later.